A detailed history of Capital International Investors transactions in Cellectis S.A. stock. As of the latest transaction made, Capital International Investors holds 1,848,804 shares of CLLS stock, worth $3.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,848,804
Previous 1,848,804 -0.0%
Holding current value
$3.36 Million
Previous $4.9 Million 29.43%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$1.83 - $3.84 $2.56 Million - $5.38 Million
1,400,000 Added 311.94%
1,848,804 $3.57 Million
Q3 2022

Nov 14, 2022

SELL
$2.29 - $4.08 $302,813 - $539,510
-132,233 Reduced 22.76%
448,804 $1.03 Million
Q2 2022

Aug 15, 2022

SELL
$2.39 - $4.93 $2.42 Million - $4.98 Million
-1,011,017 Reduced 63.5%
581,037 $1.64 Million
Q4 2021

Feb 14, 2022

BUY
$8.01 - $12.84 $2.02 Million - $3.24 Million
252,718 Added 18.87%
1,592,054 $12.9 Million
Q2 2020

Aug 14, 2020

SELL
$8.21 - $21.02 $541,039 - $1.39 Million
-65,900 Reduced 4.69%
1,339,336 $23.8 Million
Q1 2020

May 15, 2020

BUY
$7.81 - $18.82 $3.04 Million - $7.33 Million
389,300 Added 38.32%
1,405,236 $12.9 Million
Q4 2019

Feb 18, 2020

BUY
$9.73 - $19.31 $2.98 Million - $5.91 Million
306,100 Added 43.12%
1,015,936 $17.4 Million
Q3 2019

Nov 14, 2019

BUY
$10.15 - $16.89 $2.93 Million - $4.88 Million
289,144 Added 68.73%
709,836 $7.38 Million
Q2 2019

Aug 14, 2019

BUY
$14.6 - $20.6 $6.14 Million - $8.67 Million
420,692 New
420,692 $6.56 Million
Q1 2019

May 15, 2019

SELL
$15.53 - $19.75 $3.72 Million - $4.73 Million
-239,391 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$15.58 - $28.41 $3.73 Million - $6.8 Million
239,391 New
239,391 $3.99 Million

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $82.8M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.